Last reviewed · How we verify
Mitomycin C 0.02%
Mitomycin C is an alkylating agent that cross-links DNA, preventing cell division and inducing apoptosis in rapidly dividing cells.
Mitomycin C is an alkylating agent that cross-links DNA, preventing cell division and inducing apoptosis in rapidly dividing cells. Used for Prevention of conjunctival and corneal scarring following ocular surgery, Adjunctive therapy in glaucoma filtration surgery, Prevention of pterygium recurrence.
At a glance
| Generic name | Mitomycin C 0.02% |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology; Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Mitomycin C acts as a prodrug that is activated in cells to form reactive intermediates capable of covalently binding to DNA and creating interstrand cross-links. This DNA damage triggers cell cycle arrest and programmed cell death, making it effective against cancer cells and proliferating tissues. The 0.02% ophthalmic formulation is used topically to prevent scarring by inhibiting fibroblast proliferation.
Approved indications
- Prevention of conjunctival and corneal scarring in ophthalmic surgery
- Adjunctive therapy in glaucoma filtration surgery
- Prevention of pterygium recurrence
Common side effects
- Corneal toxicity
- Conjunctival scarring
- Epithelial defects
- Iritis/uveitis
Key clinical trials
- CsA vs MMC for Preventing Pterygium Recurrence (NA)
- Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain (NA)
- Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy (PHASE4)
- Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma (NA)
- Comparison Between Topical Mitomycin C and Cyclosporine (PHASE1)
- The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients (PHASE2)
- A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation. (PHASE4)
- Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin C 0.02% CI brief — competitive landscape report
- Mitomycin C 0.02% updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI